---
subject: Weekly Drug News Round-Up November 22, 2017
---

{{> header-secondary }}

<wrapper class="header header-primary">
	<container>
		<row class="collapse">
			<columns small="12" large="6" valign="middle">
				<img class="logo logo-ddc small-float-center" src="https://media.drugs.com/wp-content/uploads/2017/12/logo-ddc.png" width="212" height="44" alt="Drugs.com">
			</columns>
			<columns small="12" large="6">
				<p class="small-text-center text-right no-space" valign="middle">
					<span class="header-title">Weekly News Round-up</span><br>
					<span class="header-sub-title">November 22, 2017</span>
				</p>
			</columns>
		</row>
	</container>
</wrapper>

<container>

	<row>
		<columns small="12">
			<spacer size="30"></spacer>
			<h2>Weekly News Round-up</h2>
			<p>Novel approvals round out this busy week before Thanksgiving: Viiv Healthcare's Juluca is the first two drug (not three), fixed dose regimen for HIV maintenance, and Hemlibra is a first-in-class agent cleared for hemophilia A with inhibitors. Mepsevii is the first drug OKâ€™d for rare mucopolysaccharidosis type VII, and Sutent and Tekturna both gain new indications to add to their current labels.</p>
			<button href="#" class="radius btn-offset">Read More</button>
		</columns>
	</row>

{{> sponsored }}
	
{{> slideshow }}

</container>

{{> footer }}